Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24654963 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CCR2PRCP | |
| SCHEMBL24833572 | 0.98 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CCR2PRCP | |
| SCHEMBL21226033 | 0.98 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CCR2PRCP | |
| SCHEMBL18791407 | 0.95 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL23874154 | 0.95 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL20622101 | 0.93 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL26491308 | 0.93 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL19242291 | 0.93 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL12323874 | 0.90 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CCR2PRCP | |
| SCHEMBL20841352 | 0.89 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322754-A1 | IRAK INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322754-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A2 4852/4885SLC6A4 4849/4885SLC6A3 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.